Natco Pharma to Launch Semaglutide in India by March 2026

Natco Pharma’s Semaglutide Launch – March 2026

Hyderabad-based Natco Pharma is set to introduce generic semaglutide injections in India by March 2026, following regulatory clearance from CDSCO. The drug, widely known as the active ingredient in Novo Nordisk’s Ozempic (for type 2 diabetes) and Wegovy (for weight management), will be marketed in partnership with Eris Lifesciences.

Key Highlights

• Regulatory approval: CDSCO clears Natco Pharma to manufacture and market semaglutide in India.
• Launch timeline: Product rollout scheduled for March 2026.
• Strategic partnership: Eris Lifesciences to co-market the drug in India.
• Therapeutic use: Indicated for type 2 diabetes management and weight loss.
• Market impact: Entry expected to intensify competition in India’s diabetes and metabolic care segment.
• Patent expiry: Global patent expirations have opened opportunities for Indian generics.

This launch positions Natco Pharma as a key player in India’s expanding diabetes and obesity treatment market, offering affordable alternatives to global brands while strengthening its pharmaceutical portfolio.

Sources: The Hindu BusinessLine, Moneycontrol, CNBC-TV18